Search CTL/CD8+ T-Cell Epitope Database

Found 7 matching records:

Displaying record number 54209

Download this epitope record as JSON.

HXB2 Location	Tat(31-39) DNA(5921..5947)	Tat Epitope Map
Author Location	Tat(31-39)
Epitope	`CLHCQVCFI`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, B13, B41
Country	France
Experimental methods	Other
Keywords	computational epitope prediction, escape, acute/early infection, mutation acquisition

Notes

A longitudinal study from primary infection to 5 years postinfection was conducted to determine Tat and Rev gene evolution. 2/4 patients showed Tat gene evolution. It was found that though Tat evolved by mostly nonsynonymous, non-random sequence changes, there was no increase in transactivating capacity or size of Tat protein. Sequence evolution occurred mostly in predicted epitopes that are MHC I restricted.
Tat and Rev seem to evolve due to CTL pressure later in infection, after seroconversion, and possibly during viral replication.
The predicted epitope C(l)HCQVCFI, had a variant CfHCQVCFI in the second position.

References

Guillon2006 C. Guillon, K. Stankovic, Y. Ataman-Önal, F. Biron, and B. Verrier. Evidence for CTL-Mediated Selection of Tat and Rev Mutants after the Onset of the Asymptomatic Period during HIV Type 1 Infection. AIDS Res. Hum. Retroviruses, 22(12):1283-1292, Dec 2006. PubMed ID: 17209772. Show all entries for this paper.

Displaying record number 54210

Download this epitope record as JSON.

HXB2 Location	Rev(51-59) DNA(8453..8479)	Rev Epitope Map
Author Location	Rev(51-59)
Epitope	`QIRTYSGWI`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, B13, B41
Country	France
Experimental methods	Other
Keywords	computational epitope prediction, escape, acute/early infection, mutation acquisition

Notes

A longitudinal study from primary infection to 5 years postinfection was conducted to determine Tat and Rev gene evolution. 2/4 patients showed Tat gene evolution. It was found that though Tat evolved by mostly nonsynonymous, non-random sequence changes, there was no increase in transactivating capacity or size of Tat protein. Sequence evolution occurred mostly in predicted epitopes that are MHC I restricted.
Tat and Rev seem to evolve due to CTL pressure later in infection, after seroconversion, and possibly during viral replication.
Epitope QIRTYSGWI did not change in the subjects studied.

References

Displaying record number 54213

Download this epitope record as JSON.

HXB2 Location	Rev(63-71) DNA(8489..8515)	Rev Epitope Map
Author Location	Rev(63-71)
Epitope	`YLGGSEEPV`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, B13, B41
Country	France
Experimental methods	Other
Keywords	computational epitope prediction, escape, acute/early infection, mutation acquisition

Notes

A longitudinal study from primary infection to 5 years postinfection was conducted to determine Tat and Rev gene evolution. 2/4 patients showed Tat gene evolution. It was found that though Tat evolved by mostly nonsynonymous, non-random sequence changes, there was no increase in transactivating capacity or size of Tat protein. Sequence evolution occurred mostly in predicted epitopes that are MHC I restricted.
Tat and Rev seem to evolve due to CTL pressure later in infection, after seroconversion, and possibly during viral replication.
No variants of epitope YLGGSEEPV were found in the subjects studied.

References

Displaying record number 54211

Download this epitope record as JSON.

HXB2 Location	Rev(70-78) DNA(8510..8536)	Rev Epitope Map
Author Location	Rev(70-78)
Epitope	`PVPFQLPPL`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, B13, B41
Country	France
Experimental methods	Other
Keywords	computational epitope prediction, escape, acute/early infection, mutation acquisition

Notes

A longitudinal study from primary infection to 5 years postinfection was conducted to determine Tat and Rev gene evolution. 2/4 patients showed Tat gene evolution. It was found that though Tat evolved by mostly nonsynonymous, non-random sequence changes, there was no increase in transactivating capacity or size of Tat protein. Sequence evolution occurred mostly in predicted epitopes that are MHC I restricted.
Tat and Rev seem to evolve due to CTL pressure later in infection, after seroconversion, and possibly during viral replication.
The previously described epitope PVPFQLPPL, had a variant PVPlQLPPL in the fourth position.

References

Displaying record number 54214

Download this epitope record as JSON.

HXB2 Location	Rev(74-82) DNA(8522..8548)	Rev Epitope Map
Author Location	Rev(74-82)
Epitope	`QLPPLERLT`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, B13, B41
Country	France
Experimental methods	Other
Keywords	computational epitope prediction, escape, acute/early infection, mutation acquisition

Notes

A longitudinal study from primary infection to 5 years postinfection was conducted to determine Tat and Rev gene evolution. 2/4 patients showed Tat gene evolution. It was found that though Tat evolved by mostly nonsynonymous, non-random sequence changes, there was no increase in transactivating capacity or size of Tat protein. Sequence evolution occurred mostly in predicted epitopes that are MHC I restricted.
Tat and Rev seem to evolve due to CTL pressure later in infection, after seroconversion, and possibly during viral replication.
No variants of epitope QLPPLERLT were found in the subjects under study.

References

Displaying record number 54212

Download this epitope record as JSON.

HXB2 Location	Rev(101-109) DNA(8603..8629)	Rev Epitope Map
Author Location	Rev(101-109)
Epitope	`QILGEPPTV`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, B13, B41
Country	France
Experimental methods	Other
Keywords	computational epitope prediction, escape, acute/early infection, mutation acquisition

Notes

A longitudinal study from primary infection to 5 years postinfection was conducted to determine Tat and Rev gene evolution. 2/4 patients showed Tat gene evolution. It was found that though Tat evolved by mostly nonsynonymous, non-random sequence changes, there was no increase in transactivating capacity or size of Tat protein. Sequence evolution occurred mostly in predicted epitopes that are MHC I restricted.
Tat and Rev seem to evolve due to CTL pressure later in infection, after seroconversion, and possibly during viral replication.
The previously described epitope QILGEPPTV, contained variants QILGEhPpV in the sixth and eighth positions and QILGghPpV in the fifth, sixth and eighth positions.

References

Displaying record number 54215

Download this epitope record as JSON.

HXB2 Location	Rev(102-110) DNA(8606..8632)	Rev Epitope Map
Author Location	Rev(102-110)
Epitope	`ILGEPPTVL`	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	A2, B13, B41
Country	France
Experimental methods	Other
Keywords	computational epitope prediction, escape, acute/early infection, mutation acquisition

Notes

A longitudinal study from primary infection to 5 years postinfection was conducted to determine Tat and Rev gene evolution. 2/4 patients showed Tat gene evolution. It was found that though Tat evolved by mostly nonsynonymous, non-random sequence changes, there was no increase in transactivating capacity or size of Tat protein. Sequence evolution occurred mostly in predicted epitopes that are MHC I restricted.
Tat and Rev seem to evolve due to CTL pressure later in infection, after seroconversion, and possibly during viral replication.
The previously described epitope ILGEPPTVL varied to ILGEhPhVL in the fifth and seventh positions and ILGghPhVL in the fourth, fifth and seventh positions.